Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
Somatuline Autogel | Lanreotide acetate | Acromegaly | List in a similar manner to other drugs in class | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Pending | |||
Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete |